National Institute for Health and Care Excellence

National Institute for Health and Care Excellence
Name	National Institute for Health and Care Excellence
Type	Executive non-departmental public body
Founded	01 April 1999
Location	London, United Kingdom
Key people	Sharmila Nebhrajani (Chair), Professor Gillian Leng (Chief Executive)
Area served	England and Wales
Focus	Health technology assessment, Clinical guideline, Public health
Parent	Department of Health and Social Care
Website	https://www.nice.org.uk

National Institute for Health and Care Excellence. It is an Executive non-departmental public body of the Department of Health and Social Care that provides national guidance and advice to improve health and social care in England and Wales. Established in 1999, its role encompasses the development of evidence-based recommendations on the effectiveness and cost-effectiveness of treatments, technologies, and care pathways. The institute's guidance is instrumental in supporting decisions made by the National Health Service, local authorities, and other care providers.

History and establishment

The organisation was established on 1 April 1999 as the National Institute for Clinical Excellence, following a policy commitment in the 1997 White Paper *The New NHS*. Its creation was driven by the Labour government's desire to address perceived "postcode lotteries" in the availability of new drugs and treatments across the National Health Service. In 2005, following the Health and Social Care Act 2012, it merged with the Health Development Agency and was renamed the National Institute for Health and Clinical Excellence, expanding its remit to include public health guidance. The final name change to the National Institute for Health and Care Excellence occurred in 2013, reflecting its broader responsibilities encompassing social care following the recommendations of the Francis Report.

Functions and responsibilities

Its primary function is to develop robust, evidence-based guidance across health, public health, and social care to achieve the best possible outcomes for people. A core responsibility is conducting health technology assessments, most notably through its technology appraisals programme which evaluates the clinical and cost-effectiveness of new medicines, medical devices, and diagnostics. The institute also produces clinical guidelines that define optimal care for specific conditions, public health guidelines aimed at preventing illness, and social care guidance. Furthermore, it manages the British National Formulary and provides advice on safe staffing levels through its work with NHS England.

Guidance production process

The development of all guidance follows a meticulously defined process designed to ensure scientific rigour, transparency, and stakeholder engagement. Proposals for new topics are often referred by the Department of Health and Social Care or identified internally. Independent committees, including the Technology Appraisal Committee and various guideline committees, are convened, comprising healthcare professionals, academics, and lay members. These committees review comprehensive evidence assessments conducted by internal technical teams or external groups like the School of Health and Related Research at the University of Sheffield. Draft recommendations undergo public consultation before final approval by the institute.

Types of guidance issued

The institute issues several distinct categories of guidance to inform decision-making. Technology appraisals provide recommendations on the use of new and existing medicines and treatments within the National Health Service. Clinical guidelines offer comprehensive advice on the appropriate treatment and care of people with specific diseases and conditions, such as those developed for type 2 diabetes or depression. Interventional procedures guidance assesses the safety and efficacy of novel surgical and diagnostic techniques. Additionally, it publishes public health guidelines, which advise on activities to promote good health and prevent disease, and standards for social care.

Impact and criticism

The institute's guidance has profoundly influenced clinical practice and resource allocation within the National Health Service, standardising care and promoting the adoption of cost-effective interventions. Its technology appraisal recommendations are legally mandated for funding compliance by NHS England and NHS Wales. However, it has faced significant criticism from patient groups and the pharmaceutical industry for perceived excessive focus on cost containment, particularly through its use of the Quality-adjusted life year metric. High-profile controversies, such as initial restrictions on drugs for Alzheimer's disease and cancer treatments, have led to debates about the appropriateness of its decision-making framework and the establishment of the Cancer Drugs Fund.

Organisational structure and governance

The institute operates as an Executive non-departmental public body, sponsored and funded by the Department of Health and Social Care. Its governance is led by a board appointed by the Secretary of State for Health and Social Care, currently chaired by Sharmila Nebhrajani. The chief executive, Professor Gillian Leng, oversees the executive team and the institute's operational delivery. Its work is supported by several centre directors managing distinct programmes, such as the Centre for Guidelines and the Centre for Health Technology Evaluation. Key advisory committees, including the Technology Appraisal Committee and the Public Health Advisory Committee, provide independent expert input into the guidance development process.

Category:Health care in the United Kingdom Category:Medical and health organisations based in the United Kingdom Category:1999 establishments in the United Kingdom